RT Journal Article
T1 Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain
A1 Jiménez Ruiz, Carlos Andrés
A1 Solano Reina, Segismundo
A1 Signes Costa, Jaime
A1 de Higes Martínez, Eva
A1 Granda Orive, José Ignacio De
A1 Lorza Blasco, José Javier
A1 Riesco Miranda, Juan Antonio
A1 Altet Gomez, Neus
A1 Barrueco Ferrero, Miguel
A1 Oyagüez, Itziar
A1 Rejas, Javier
AB The aim of the study was to assess the budgetary impact of funding smoking-cessation drugs in COPD patients in Spain. A hybrid model (cohort and Markov) was developed for a 5-year time horizon. Only approved cessation drugs (varenicline, bupropion, and nicotine replacement therapy) were considered. Irrespective of the drug, the model allowed for an initial cessation attempt, and up to three additional attempts in case of failure or smoking relapse during a 5-year period. Drug effectiveness was based on controlled clinical trials. National Health System perspective was applied; therefore, only medical resources were included. The pharmaceutical costs for smoking-cessation drugs, extra medical follow-up as a consequence of public reimbursement, and annual savings for health costs avoided due to stopping smoking were considered. The model estimated that 17,756 COPD patients would stop smoking if public funding was available, compared with 1,303 without reimbursement. In the reimbursement scenario, the savings accounted for a total of €48.0 million, compensating for expenditures on drugs and medical visits (€40.4 million). Accumulated total additional savings in 5 years (€4.3 million) compared with the scenario without reimbursement was shown. Sensitivity analyses supported the results robustness. Funding smoking-cessation drugs in COPD patients seems to be an efficient option and a National Health System drug reimbursement scheme would represent a cost-saving policy in Spain.
PB Dove Medical Press
YR 2015
FD 2015-09-24
LK https://hdl.handle.net/20.500.14352/97234
UL https://hdl.handle.net/20.500.14352/97234
LA eng
NO Jiménez-Ruiz CA, Solano-Reina S, Signes-Costa J, de Higes-Martinez E, Granda-Orive JI, JJ LorzaBlasco, Riesco-Miranda JA, Altet-Gomez N, Barrueco M, Oyagüez I, Rejas J. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain. Int J COPD. 2015;10: 2027–36. DOI: 10.2147/COPD.S87597
NO Ninguna
NO Pfizer
DS Docta Complutense
RD 4 abr 2025